|
1
|
Lewandowski RJ, Sato KT, Atassi B, Ryu RK,
Nemcek AA Jr, Kulik L, Geschwind JF, Murthy R, Rilling W, Liu D, et
al: Radioembolization with 90Y microspheres: Angiographic and
technical considerations. Cardiovasc Intervent Radiol. 30:571–592.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Murthy R, Xiong H, Nunez R, Cohen AC,
Barron B, Szklaruk J, Madoff DC, Gupta S, Wallace MJ, Ahrar K, et
al: Yttrium 90 resin microspheres for the treatment of unresectable
colorectal hepatic metastases after failure of multiple
chemotherapy regimens: Preliminary results. J Vasc Interv Radiol.
16:937–945. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stuart JE, Tan B, Myerson RJ,
Garcia-Ramirez J, Goddu SM, Pilgram TK and Brown DB: Salvage
radioembolization of liver-dominant metastases with a resin-based
microsphere: Initial outcomes. J Vasc Interv Radiol. 19:1427–1433.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Piana PM, Bar V, Doyle L, Anne R, Sato T,
Eschelman DJ, McCann JW, Gonsalves CF and Brown DB: Early arterial
stasis during resin-based yttrium-90 radioembolization: Incidence
and preliminary outcomes. HPB Oxf. 16:336–341. 2014. View Article : Google Scholar
|
|
5
|
Saxena A, Meteling B, Kapoor J, Golani S,
Morris DL and Bester L: Is yttrium-90 radioembolization a viable
treatment option for unresectable, chemorefractory colorectal
cancer liver metastases? A large single-center experience of 302
patients. Ann Surg Oncol. 22:794–802. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Hazel GA, Heinemann V, Sharma NK,
Findlay MP, Ricke J, Peeters M, Perez D, Robinson BA, Strickland
AH, Ferguson T, et al: SIRFLOX: Randomized phase III trial
comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus
mFOLFOX6 (plus or minus bevacizumab) plus selective internal
radiation therapy in patients with metastatic colorectal cancer. J
Clin Oncol. 34:1723–1731. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Food and Drug Administration, . Available
at. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/PMAApprovals/ucm431264.htmAccessed
on June 15, 2016.
|
|
8
|
Gordon AC, Gradishar WJ, Kaklamani VG,
Thuluvath AJ, Ryu RK, Sato KT, Gates VL, Salem R and Lewandowski
RJ: Yttrium-90 radioembolization stops progression of targeted
breast cancer liver metastases after failed chemotherapy. J Vasc
Interv Radiol. 25:1523–1532, 1532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lewandowski RJ, Memon K, Mulcahy MF,
Hickey R, Marshall K, Williams M, Salzig K, Gates VL, Atassi B,
Vouche M, et al: Twelve-year experience of radioembolization for
colorectal hepatic metastases in 214 patients: Survival by era and
chemotherapy. Eur J Nucl Med Mol Imaging. 41:1861–1869. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kennedy AS, Nutting C, Coldwell D, Gaiser
J and Drachenberg C: Pathologic response and microdosimetry of
(90)Y microspheres in man: Review of four explanted whole livers.
Int J Radiat Oncol Biol Phys. 60:1552–1563. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pierce LR, Gaines A, Finlayson JS,
Varricchio F and Epstein JS: Hemolysis and acute renal failure due
to the administration of albumin diluted in sterile water.
Transfusion. 39:110–111. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ramaswamykanive H and Greaves J:
Intravenous infusion of sterile water for the treatment of
hypernatraemia. Anaesth Intensive Care. 42:258–262. 2014.PubMed/NCBI
|
|
13
|
Liao JC, Hein TW, Vaughn MW, Huang KT and
Kuo L: Intravascular flow decreases erythrocyte consumption of
nitric oxide. Proc Natl Acad Sci USA. 96:8757–8761. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vaughn MW, Huang KT, Kuo L and Liao JC:
Erythrocytes possess an intrinsic barrier to nitric oxide
consumption. J Biol Chem. 275:2342–2348. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rother RP, Bell L, Hillmen P and Gladwin
MT: The clinical sequelae of intravascular hemolysis and
extracellular plasma hemoglobin: A novel mechanism of human
disease. JAMA. 293:1653–1662. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Clark DA, Butler SA, Braren V, Hartmann RC
and Jenkins DE Jr: The kidneys in paroxysmal nocturnal
hemoglobinuria. Blood. 57:83–89. 1981.PubMed/NCBI
|
|
17
|
Hirsch DP, Holloway RH, Tytgat GN and
Boeckxstaens GE: Involvement of nitric oxide in human transient
lower esophageal sphincter relaxations and esophageal primary
peristalsis. Gastroenterology. 115:1374–1380. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sato KT, Omary RA, Takehana C, Ibrahim S,
Lewandowski RJ, Ryu RK and Salem R: The role of tumor vascularity
in predicting survival after yttrium-90 radioembolization for liver
metastases. J Vasc Interv Radiol. 20:1564–1569. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Geschwind JF, Ramsey DE, Cleffken B, van
der Wal BC, Kobeiter H, Juluru K, Hartnell GG and Choti MA:
Transcatheter arterial chemoembolization of liver tumors: Effects
of embolization protocol on injectable volume of chemotherapy and
subsequent arterial patency. Cardiovasc Intervent Radiol.
26:111–117. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chao C, Dagli M, Mondschein J,
Stavropoulos W, Sudheendra D, Nadolski G, et al: Effect of
substituting 50% issue for sterile water as the delivery medium for
SIR-SPHERES: Improved dose delivery and decreased incidence of
stasis. J Vasc Interv Radiol. 2:S892014. View Article : Google Scholar
|
